Interesting study from Germany (presented at the Sexual Medicine Society of North America 18th Annual Fall Scientific Meeting in San Antonio, Texas).
"Ahmad Haider, MD, in private urology practice in Bremerhaven, Germany, and colleagues studied 400 hypogonadal men (testosterone level of 350 ng/dL or less) who received testosterone undecanoate 1000 mg every 3 months for up to 10 years and 376 hypogonadal men who opted against TRT (control group). During a median follow-up of 8 years, 9 men in the TRT group (2.3%) were diagnosed with PCa compared with 26 (6.9%) in the control group. "
“In the testosterone group, all prostate cancers were diagnosed within the first year and a half suggesting that cancers had been present prior to initiating testosterone therapy,” Dr Haider said.
"All {9} men in the TRT group underwent radical prostatectomy (RP), and all but 1 patient had a Gleason score of 6 or less. All had a predominant Gleason score of 3 and all had a tumor grade of G2 and tumor stage T2. In the control group, 18 underwent RP alone, 6 underwent RP and radiation, and 2 had radiation alone. All 26 patients had a Gleason score above 6, and 2, 20, and 4 had a predominant Gleason score of 3, 4, and 5, respectively. Tumor grade was G2 in 6 patients (23%) and G3 in 20 (77%). One patient (4%) had tumor stage T2 and 25 had tumor stage T3."
renalandurologynews.com/pro...
Much is made of declining male fertility, but little about the concomitant fall in testosterone [T]. The study result suggests that younger men should monitor T & supplement, if necessary, to reduce PCa risk. & the target T should be much higher than hypogonadal 350 ng/dL IMO.
-Patrick